Skip links

Driving Business Growth with Next-Generation Recommendation Engines 

Jump To Section

Driving Business Growth with Recommendation Engines

Today, personalized user experiences have moved from being a nice-to-have, to a non-negotiable demand. To the point where customers are often put off by generic recommendations. In fact, around 71% express frustration at impersonal experiences. As businesses realize the immense opportunity that lies within the space, the obvious question arises – how does one maximize yields via personalized recommendations? 

This curiosity has given rise to an industry of recommendation engines that help businesses upsell, cross-sell, and drive favorable business outcomes. But recommendation engines aren’t straightforward. Due to modern consumer demands and a slew of technical limitations, there’s often a sizable gap between what a customer wants and the reality on their screens – oftentimes generic, clunky, and irrelevant suggestions. 

Challenges with Recommendations

Data Privacy: While personalization is non-negotiable, customers also simultaneously demand data security and integrity. But often organizations struggle to maintain the sanctity of data integrity, as most recommendation engines demand the user data be moved outside of the company’s firewall or to the cloud. 

Cold starts: Businesses also struggle with handling new users – the ‘cold start’ problem. Often this can result in irrelevant or generic recommendations which can do more harm than good.

Business constraints: Many recommendation engines don’t have provisions to accommodate for business constraints i.e. critical industry- or regulatory-specific exceptions. This results in recommendations that are impractical at best or unlawful at worst. 

Accessibility: Several recommendation engines are advanced and require a high degree of expertise. Often data scientists need to step in to glean insights, raising the barrier to entry even higher. 

These challenges were more than mere observations, they were core to our strategy when we set out to solve the challenges surrounding generic recommendations.

Enter Generic Recommendation Engine (GRE)

GRE is our take on the modern recommendation engine. It’s an industry-agnostic ensemble of AI and ML algorithms that accurately generates relevant recommendations. A pragmatic and scalable accelerator, emphasizing security, efficiency, and user-friendliness – it checks all the boxes for modern enterprises. What does it do differently? 

  • In a departure from the general notion of recommendation engines, GRE is adept at handling B2B use cases just as effectively as B2C ones.
  • It can deal with a wide variety of datasets including interaction data, product information as well as user data. 
  • Addressing the industry’s sacrosanct need for user privacy, GRE operates securely within a company’s firewall, offering end-to-end deployment in the client’s environment.
  • It also addresses the aforementioned cold start issue by dedicating a constituent model that primarily works on product information, not needing any customer information to generate engaging recommendations. 
  • It lets users adjust hyperparameters for their specific use cases, thus allowing for recommendations that account for the various business constraints across industries.  
  • GRE doesn’t need data science expertise on the client side. The system facilitates easy deployment, integration, and maintenance, streamlining the overall UX.

SDG: The GenAI Catalyst

GRE’s capabilities are further enhanced by our in-house synthetic data generator (SDG) – a GenAI-powered accelerator for when there’s inadequate data. It works in tandem with GRE for accurately recognizing complex patterns leveraging schema and metadata to fill the gaps and ensure appropriate recommendations at all times. 

Most real-world datasets are non-linear, meaning many ML algorithms struggle to learn the patterns within. The GenAI model used in GRE, with its array of complex and comprehensive learning parameters, remains resilient in the face of non-linear data – understanding even the subtlest patterns and behaviors of customers.

For instance, a new customer only has a tiny set of invoice/ transaction data available. In such cases, a conventional AI model won’t be able to successfully learn their purchase patterns and behaviors, resulting in a low-quality recommendation. With SDG, however, organizations can create synthetic invoice data for said customer. This would mimic their behavior, enabling the model to learn better. 

SDG can execute row-level augmentation of existing data, meaning all the distributional properties and relationships of the original data are conserved. For accurate trend analysis and forecasting, it works with time series data generation to stay ahead of the curve. 

GRE + SDG in action

Once implemented, how this translates looks different across industries. The common thread being a positive impact on the bottom line. For financial industries, GRE and SDG help with cross-selling and upselling. Thereafter, businesses can offer recommendations for marketing campaigns specific to the products. Similarly, in the retail and manufacturing domain, better recommendations can help price/discount products competitively to better penetrate categories. It speaks to the breadth of the use cases GRE and SDG can be deployed within. Regardless of whether it’s a B2B or B2C application, they remain unfazed, a testament to their generic nature.  

GRE + SDG in action

Manifesting Business Growth

A robust recommendation engine isn’t just a tool; it’s a catalyst for business growth. In an increasingly consumer-centric world, embracing Generative AI to maximize customer engagement becomes essential. As businesses navigate this new era, those who hesitate risk falling behind. With advanced recommendation engines like GRE, businesses gain actionable insights that fuel growth strategies and drive informed decision-making. It’s not just about recommendations; it’s about leveraging every opportunity to make a tangible business impact. 

Picture of Aman Savaria

Aman Savaria

Latest Reads

Subscribe

Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Vikas Krishan

Chief Digital Business Officer and Head of the EMEA region

Vikas (Vik) Krishan serves as the Chief Digital Business Officer and Head of the EMEA region for Altimetrik. He is responsible for leading and growing the company’s presence across new and existing client relationships within the region.

Vik is a seasoned executive and brings over 25 years of global experience in Financial Services, Digital, Management Consulting, Pre- and Post-deal services and large/ strategic transformational programmes, gained in a variety of senior global leadership roles at firms such as Globant, HCL, Wipro, Logica and EDS and started his career within Investment Banking. He has developed significant cross industry experience across a wide variety of verticals, with a particular focus on working with and advising the C-Suite of Financial Institutions, Private Equity firms and FinTech’s on strategy and growth, operational excellence, performance improvement and digital adoption.

He has served as the engagement lead on multiple global transactions to enable the orchestration of business, technology, and operational change to drive growth and client retention.

Vik, who is based in London, serves as a trustee for the Burma Star Memorial Fund, is a keen photographer and an avid sportsman.

Megan Farrell Herrmanns

Chief Digital Officer, US Central

Megan is a senior business executive with a passion for empowering customers to reach their highest potential. She has depth and breadth of experience working across large enterprise and commercial customers, and across technical and industry domains. With a track record of driving measurable results, she develops trusted relationships with client executives to drive organizational growth, unlock business value, and internalize the use of digital business as a differentiator.

At Altimetrik, Megan is responsible for expanding client relationships and developing new business opportunities in the US Central region. Her focus is on digital business and utilizing her experience to create high growth opportunities for clients. Moreover, she leads the company’s efforts in cultivating and enhancing our partnership with Salesforce, strategically positioning our business to capitalize on new business opportunities.

Prior to Altimetrik, Megan spent 10 years leading Customer Success at Salesforce, helping customers maximize the value of their investments across their technology stack. Prior to Salesforce, Megan spent over 15 years with Accenture, leading large transformational projects for enterprise customers.

Megan earned a Bachelor of Science in Mechanical Engineering from Marquette University. Beyond work, Megan enjoys playing sand volleyball, traveling, watching her kids soccer games, and is actively involved in a philanthropy (Advisory Council for Cradles to Crayons).

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes